REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
33 hedge funds and large institutions have $14.9M invested in REVIVA PHARMA HLDGS INC in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 5 closing their positions.
220% more call options, than puts
Call options by funds: $422K | Put options by funds: $132K
71% more capital invested
Capital invested by funds: $8.75M → $14.9M (+$6.19M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
6% more funds holding
Funds holding: 31 → 33 (+2)
0.35% more ownership
Funds ownership: 1.15% → 1.5% (+0.35%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.54M |
| 2 |
Millennium Management
New York
|
+$657K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$558K |
| 4 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
+$66.6K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$51.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$1.01M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$263K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$145K |
| 4 |
ECM
EMC Capital Management
Houston,
Texas
|
-$117K |
| 5 |
Morgan Stanley
New York
|
-$13.1K |
RVPH Hedge Fund Activity: Q3 2024 in Review
33 of the 6,970 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q3 2024, worth a combined $14.9M — up 71% from $8.75M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RVPH positions and 5 closed out — a net gain of 3 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.54M. The largest seller was Woodline Partners, cutting an estimated $1.01M.
- 33 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q3 2024, up from 31 in Q2 2024.
- Funds reported $14.9M of REVIVA PHARMA HLDGS INC stock for Q3 2024, up 71% quarter-over-quarter.
- 8 funds opened new REVIVA PHARMA HLDGS INC positions in Q3 2024 and 5 closed out, a net change of +3 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q3 2024 was Armistice Capital, an estimated $3.54M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q3 2024 was Woodline Partners, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2024.